IVIg TREATMENT OF PEMPHIGUS: How it Works and How to Use it  by Bystryn, Jean-Claude et al.
g
oundation
oloDermat
F
y
Introduction
The treatment of pemphigus is one of the miracles of
modern medicine. A disease that was once almost
invariably fatal [1] has been transformed into one whose
mortality is now only 5% to 10%. The mainstay of current
therapy is the administration of systemic steroids in
doses high enough to suppress the manifestations of the
disease [2]. In addition, immunosuppressive (azathio-
prine, cyclophosphamide, mycophenolate mofetil,
methotrexate), or immunomodulatory (dapsone, gold,
antibiotics) drugs are often used as adjuvants as they
may reduce the need for, and side effects of, systemic
steroids. However, the effectiveness of these adjuvants
has not been established objectively in a randomized
trial. 
Pemphigus is caused by autoantibodies (pemphigus
antibodies) directed against adhesion molecules on the
surface of keratinocytes [3,4]. In pemphigus vulgaris the
antibodies are directed against desmoglein-3 and in
about 50% of patients are also directed against
desmoglein-1. In pemphigus foliaceus, the antibodies
are all directed against desmoglein-1. It is possible that
other autoantibodies may be involved. The involvement
of pemphigus antibodies in the pathogenesis of the
disease is evidenced by their selective presence in 
patients with pemphigus, the relation between their titer
and disease activity [3], the rapid improvement in
disease activity when antibodies are physically removed
by plasmapheresis [5], and most convincingly by the
ability of the antibodies to induce pemphigus when given
to mice [6]. 
The need for better treatments for pemphigus
Despite the impressive progress treating pemphigus,
better therapies are required. 1) No current treatment
addresses the basic pathology of the disease, i.e. that
pemphigus is caused by one or a few abnormal antibod-
ies in the blood. Rather than selectively removing only
the abnormal antibodies, current treatments non-specifi-
cally affect all antibodies – the good with the bad, which
results in undesirable toxicities. 2) Pemphigus cannot be
controlled in some cases even with very high doses of
steroids. In other cases, treatment cannot be tapered
without a flare in disease activity, or patients cannot
tolerate side effects of the treatment. 3) Lastly, there is a
need for adjuvant therapies that will more reliably
minimize the use and side effects of steroids – which
currently are the major cause of death in pemphigus.
IVIg appears to provide a partial solution to these
challenges. 
Editor: Alan N. Moshell, M.D.
Published by the
Progress in
Dermatology
The production of this issue of Progress in Dermatology
has been underwritten by Galderma Laboratories, L.P.
©2005 Dermatology Foundation, 1560 Sherman Avenue, Evanston, Illinois 60201
IVIg TREATMENT OF PEMPHIGUS:
How it Works & How to Use it
Jean-Claude Bystryn, M.D. and Jennifer L. Rudolph, M.D.
Ronald O. Perelman Department of Dermatology
New York University School of Medicine
New York, NY
To cite this article: J Invest Dermatol 125:1093–1098, 2005
1093
What is IVIg?
Intravenous immunoglobulin, or IVIg, refers to the
intravenous administration of immunoglobulin. The
immunoglobulin is prepared from plasma pooled from
thousands of donors. It consists mostly of intact IgG
molecules, with traces of IgA and of some cytokines and
other immunomodulators found in serum. It contains the
broad range of normal antibodies present in healthy
individuals. Seven different formulations of IVIg were
licensed in the US in 2002, each prepared somewhat
differently. Their properties are summarized in Table I.
As the composition of these preparations differ depend-
ing on the manufacturer [7], so does their effects, partic-
ularly their potential side effects. Clinically, the most
relevant differences in composition are IgA, salt and
sugar content, volume and osmolarity [7]. Preparations
low in IgA are best for patients who are IgA - deficient
and who may have anti-IgA antibodies (to minimize the
risk of anaphylaxis). Low levels of sodium are best for
patients with hypertension, cardiac and/or renal disease
or those who are on a low salt diet. Low glucose prepa-
rations are best for diabetics, while those containing
sucrose have been associated with adverse renal
events. Preparations given in high concentration are best
to minimize fluid overload in patients with impaired
cardiac or renal function. Osmolarity, which is mostly
related to salt, sugar and amino acid content, can cause
fluid shifts and infusion-related adverse events [7].
Finally, various procedures are used to inactivate or
remove virus from the plasma, and these differ in
their effectiveness. Ig is expensive, costing approxi-
mately $10,000 for a single cycle of treatment, and
multiple cycles of therapy are normally required. 
How is IVIg used?
Important variables in using IVIg are dose, rate of
infusion, the number of days over which it is given (a
cycle), and the frequency with which cycles are
repeated. The dose is usually 2 gm of Ig/kg per
cycle, administered over 2 to 5 days. For example,
400 mg/kg can be given daily for 5 days or 500
mg/kg daily for 4 days. The faster the IVIg is given
(by increasing the rate of administration and short-
ening the number of days over which it is given) the
more convenient for the patient and the less the
expense but the greater the chances for complica-
tions. Each daily infusion is normally given over 4-5
hours. Complications increase as the speed of
administration increases. The optimal frequency with
which cycles should be repeated or the number of
cycles administered to treat pemphigus is not
known. IVIg has been used frequently (every 2
weeks) for a limited number of cycles [3-5] to rapid-
ly control active disease [8]; or monthly and then at
increasingly longer intervals for prolonged periods
(several years) to manage chronic disease [9]. As
the treatment is expensive, what and how it is done
is influenced by the reimbursement policies of insurance
companies, which are not consistent. The treatment is
usually given in an infusion center, an appropriately
equipped physician’s office, or in-hospital if the potential
for complications is high. Commercial services will
provide treatment at home, which is very convenient for
the patient; however, precautions must be taken to
handle any potential complications. 
Mechanism of action of IVIg in pemphigus
The mechanism of action of IVIg in most autoimmune
diseases remains uncertain [10]. In pemphigus however,
it seems to work by rapidly, dramatically, and selectively
lowering serum levels of pemphigus antibodies. 
We have found that one week after a single cycle of
IVIg, the average level of pemphigus antibodies
decreased by an average of 70% [8]. The results in a
representative patient are illustrated in Fig 1. The rate of
decrease in pemphigus antibodies is as rapid as that
induced when pemphigus antibodies are removed
physically by plasmapheresis, and much more rapid than
with conventional treatment with high doses of steroids
and cytotoxic drugs where antibody levels decrease by
only 16% after 3 weeks [11]. The magnitude of the
decrease in antibody levels varies among patients – it is
dramatic in some, minimal in others. We believe this
diversity reflects in part variations in the ability of differ-
ent individuals to synthesize pemphigus antibodies, with
a few individuals being able to do so as rapidly as it 
is depleted. 
The decrease in pemphigus antibodies associated
with IVIg treatment is highly selective. There is no
decrease in the levels of unrelated antibodies, as 
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FIGURE 1
Fig 1. Effect of IVIg treatment on serum levels of pemphigus antibodies
in a representative patient. Pemphigus antibodies were measured 
by indirect immunofluorescence at baseline immediately prior to
administration of IVIg and following 5 daily IV infusions of Ig at a dose 
of 400 mg/kg/day. Note that one week following initiation of the 
treatment, pemphigus antibody levels were 70% lower than the 
pre-treatment level. 
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illustrated in Fig 2. Thus, IVIg can achieve the gold
standard sought in the treatment of autoimmune
diseases – suppressing the presence of abnormal
antibodies but not that of normal antibodies. 
How does IVIg rapidly and selectively decrease
serum levels of only pemphigus antibodies? Three 
possibilities could account for the decrease in pemphi-
gus antibodies associated with IVIg therapy. Of these,
the last is the most likely. The possibilities include:
1) IVIg blocks the synthesis of pathogenic antoanti-
bodies. However, this is unlikely to be the full explanation
as it cannot account for the very rapid decrease in
pemphigus antibody levels that actually occur. The half-
life of lgG in the circulation is approximately 3 weeks.
Even if IVIg immediately and completely blocked all lgG
synthesis, the level of pemphigus antibodies would
decrease maximally by 50% in 3 weeks, far slower than
the 50% or more in 1 week that actually occurs. 2) The
presence of blocking factors in the IVIg preparation
(such as anti-id antibodies) that inactivate or block the
reactivity of pemphigus antibodies. This possibility is
excluded by experiments in which we incubated the IVIg
preparation used to treat patients with pre-treatment
pemphigus antibodies obtained from several patients.
There was no decrease in the level of pemphigus
antibodies as measured by indirect immunofluores-
cence, 3) Increased catabolism. By exclusion, this
appears to be the most viable explanation and as
described below also explains how the decrease will 
be selective.
Our hypothesis is that IVIg stimulates a very rapid
increase in the catabolism of all serum antibodies, and
that this results in a decrease of only abnormal anti-
bodies (pemphigus antibodies) as the normal antibodies
which are also catabolized are replaced by those present
in the Ig preparation. 
Supporting this hypothesis: 1) There exists a physio-
logical feedback mechanism which maintains constant
total serum level of Ig. Increases in serum IgG acceler-
ates the catabolism of all IgG molecules so reduce their
serum levels back to normal. This is believed to occur as
a result of the saturation of FcRn
receptors that normally protect IgG
molecules from degradation inside
cells [12]. 2) This mechanism should
be activated by IVIg treatment, which
increases serum levels of Ig by 
approximately 50%. 3) The rate at
which serum Ig level returns to normal
(an indication of catabolic rate) once
IVIg therapy is discontinued is similar
to the rate at which serum level of
pemphigus antibodies decreases [8].
4) Serum levels of pemphigus anti-
bodies decrease most rapidly when
total serum Ig levels are highest, and
no longer change once total Ig levels
return to normal [8]. As discussed
subsequently, this mechanism of
action suggests a way to improve the
effectiveness of IVIg treatment.
The mechanism of action of IVIg is
very similar to that of plasmapheresis.
Both procedures rapidly remove 
circulating pemphigus antibodies from
the circulation and do so at about
equal rates. However, IVIg has the major advantages
over plasmapheresis that the pemphigus antibodies are
removed selectively, whereas plasmapheresis as usual-
ly performed removes all circulating immunoglobulins,
the good with the bad. Furthermore, IVIg appears to 
be safer.
Results of IVIg in the treatment of pemphigus
Individual case reports [see 13 for review] and sever-
al larger studies [8,9,14,15] indicate that IVIg can be an
effective treatment for both pemphigus vulgaris and
foliaceus. It is used in two distinct manners – as a short
- term treatment to control active disease unresponsive
to conventional therapy and as a long - term treatment
for the management of chronic disease. 
Active pemphigus unresponsive to high doses of
prednisone (60-280 mg/day), given together with an
immunosuppressive drug in half the cases, has been
treated with one to 3 cycles of IVIg given every 2 to 3
weeks in 6 patients [8]. The disease was controlled in
most patients within 2 weeks, and prednisone doses
could be reduced within 3 weeks by an average of 40%
from baseline level immediately pre-infusion. Similar
results were observed when the study was extended to
a total of 12 patients. Others have reported similar rapid
response of extensive and rapidly progressive pemphi-
gus to IVIg treatment [14]. However, not all patients
respond equally well to treatment. In some, one cycle of
IVIg is sufficient to clear most skin lesions within two
weeks; in others, even several cycle of IVIg has little
impact on the extent of disease. In part this variation
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FIGURE 2
Fig 2. Effect of IVIg on serum levels of pemphigus and of a normal (VHZ = varicella-herpes zoster)
antibodies in 4 patients. All patients had both types of antibodies in their serum prior to IVIg 
treatment. One week following initiation of therapy with a single cycle of IVIg, serum levels of
pemphigus antibodies decreased by an average of 66% , while those of VHZ antibodies 
actually increased. 
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appears to be related to the ability of the treatment to
lower serum levels of pemphigus antibodies, which in turn
is probably related to the class and/or the pathogenicity of
the pemphigus antibodies that are affected by the IVIg
procedure, the rate at which new antibody is synthesized,
by the frequency of the IVIg procedures and as discussed
later by the use of cytotoxic agents to minimize new
antibody synthesis.
In chronic, long standing pemphigus, two trials have
been conducted, one in pemphigus vulgaris (n=21) [9],
the other in pemphigus foliaceus (n=11) [15]. In both
trials, a heterogeneous population of patients with either
an unsatisfactory response to therapy or significant side
effects was treated. IVIg was given monthly until all
lesions were healed, and then at increasingly longer inter-
vals until patients were disease-free for 16 weeks. In both
studies, patients became lesion-free after a mean of 4.5
to 5.3 months. Eventually systemic therapy could be
terminated in all patients. Patients required an average of
18-19 cycles of IVIg given over an average of 27-30
months. The ability to induce a remission in all of these
patients is impressive. However, this positive result must
be weighed against the expense and potential risk 
of repeated administrations of IVIg, given over 
several years. 
Procedures to improve the effective-
ness of IVIg treatment: 
The mechanism of action of IVIg described
above suggests two approaches to improve
its clinical effectiveness. 
1) IVIg is believed to work by lowing serum
levels of pemphigus antibodies. Thus, one
simple way to improve effectiveness is simply
to increase the frequency of treatment, i.e. by
administering it every 2 weeks rather than
once a month. One cycle of IVIg will lower
serum levels of pemphigus antibodies by
approximately 50-60% under optimal condi-
tions. Frequent monitoring of serum levels of
pemphigus antibodies during IVIg therapy will
help monitor the effectiveness of the treat-
ment and how long it should be continued. 
2) The effectiveness of IVIg treatment can
also be improved, we believe, by co-adminis-
tering a cytotoxic drug such as cyclophos-
phamide or azathioprine, in order to minimize
the “rebound” in pemphigus antibody levels
that may otherwise occur. 
A physiological regulatory feedback
mechanism maintains constant the level of
individual antibodies in serum, and triggers
new synthesis of any antibody whose level
is lowered [16]. The feedback causes a rapid
rebound in the serum level of any antibody that is deplet-
ed, which can exceed that present prior to the depletion
(as illustrated in Fig 3). This feedback mechanism will limit
the effectiveness of any treatment that reduces serum
levels of individual autoantibodies. 
We have previously shown that the rebound can be
reduced in animals [16] and in humans [17] by using
cytotoxic drugs which inhibit antibody synthesis. The
result of using cyclophosphamide to suppress the
rebound in serum levels of a single antibody that follows
its abrupt depletion by exchange plasmapheresis in
animals is illustrated in Fig 3. The use of cytotoxic agents
is now commonly accepted to improve the effectiveness
of plasmapheresis treatment of pemphigus [18], by
minimizing the rebound in pemphigus antibodies that
would otherwise occur. We believe the same approach
should improve the effectiveness of IVIg treatment, which
like plasmapheresis, causes a rapid and profound decline
in serum levels of pemphigus antibodies. Support for this
suggestion comes from: a) case reports of IVIg therapy of
pemphigus describe the procedure as clinically effective
when a cytotoxic agent is given concurrently [19-21] and
as ineffective when such an agent is not used [22,23]; b)
our own studies where IVIg more rapidly controlled
disease activity and lowered serum pemphigus antibody
levels when given with an effective dose of cyclophos-
phamide or azathioprine than without; and c) reports that
months are required for IVIg to lower serum levels of
pemphigus antibodies when administered without a
cytotoxic agent, while the decrease occurs in days to
weeks if a cytotoxic drug is used.
Precautions and side effects
IVIg has the potential to cause serious side effects and
thus should only be used in situations where its potential
risk/benefit ratio outweighs that of alternate therapies.
Patients who are IgA deficient, who have cardiac or renal
disease or migraines are at particular risk of developing
serious complications.
FIGURE 3
Fig 3. The “rebound” in antibody level that follows depletion in the serum level of that
antibody, and suppression of the rebound by cyclophosphamide. Exchange transfusion was
used to abruptly lower serum levels of a single antibody (anti-KLH) in a group of 15 mice. 
Half the mice were then treated with cyclophosphamide. There was a rapid rebound in serum in
anti-KLH antibody levels in the mice not treated with cyclophosphamide (upper curve), so that
2 weeks later the average serum levels of that antibody were almost twice the baseline levels.
By contrast, the rebound in mice treated with cyclophosphamide was markedly suppressed
(lower curve). 
PREVENTION OF ANTIBODY REBOUND
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Screening studies done prior to initiation of therapy
include serum Ig level (to look for IgA deficiency which is
associated with increased chance of anaphylaxis),
hepatic and renal function tests and urinalysis (to look for
renal dysfunction), blood pressure (to look for cardiac
disease), and serum immune complexes. Pemphigus
antibodies should be obtained at baseline and periodi-
cally during therapy to monitor changes in their levels. 
Pretreatment with non-steroidal anti-inflammatory
agents (acetaminophen 650 mg) and antihistamines
(diphenhydramine 50 mg) can minimize infusion-related
headaches, rigors and other adverse events [15].
Mild side effects, usually infusion related, occur in
approximately 5% to 15% of patients. These include
fever, headache, muscle pains, low back pain, chills
nausea, vomiting, and fatigue, changes in blood
pressure, difficulty breathing, chest tightness, flushing,
and infusion site reactions. These effects usually occur
within 30 min. of initiating the infusion. They can be
relieved by reducing the infusion rate or temporarily
stopping it [24]. Acute aseptic meningitis, which may
occur within 2 to 3 days after the infusion, can be
minimized by anti-inflammatory drugs, and normally
resolves spontaneously [10].
More serious side effects are unusual. They include
anaphylaxis (most common with pre-existing IgA
deficiency), thrombosis and strokes, renal dysfunction
including acute renal failure (more common in patients
treated with Ig preparations prepared from powder or
those containing sucrose), infection, hemolysis, worsen-
ing of pre-existing congestive heart failure, and severe
headache (particularly common in patients with a history
of migraine). Because the Ig is prepared from large
batches of pooled human plasma, there is a potential risk
of transmitting infectious agents. To the best of our
knowledge, no case of IVIg transmitted HIV or
Creutzfeldt-Jakob disease has been reported. There
were several outbreaks of hepatitis C linked to IVIg in the
past, but this risk has been reduced by advances in the
manufacturing process. 
Indications for IVIg
There is general agreement that IVIg is indicated for
the control of pemphigus unresponsive to conventional
therapy, or when a serious complication to standard
therapy occurs. Other suggested indications include
inability to withdraw steroids without a flare in disease
activity, absolute or relative contraindications to the use
of systemic steroids, and progressive disease despite
appropriate but safe conventional therapy [25]. An
important element in the decision are the policies of
Medicare or of he insurance plan that will pay for the
treatment. The indications vary with each plan, and
Medicare’s indication vary from region to region in the
US. A helpful guide to the regulatory and reimbursement
issues involved in treating patients with IVIg is provided
in reference 26. 
A major advance in assuring reimbursement for the
IVIg treatment of pemphigus was Medicare’s issue of a
National Coverage Decision in 2002 providing for cover-
age of IVIg treatment of biopsy proven pemphigus and
other autoimmune blistering diseases, provided the
patient met at least one of the following criteria: 1) Failed
conventional therapy; 2) conventional therapy is other-
wise contraindicated; or 3) rapidly progressive disease in
whom a clinical response cannot be affected quickly
enough using conventional therapy [27]. However, the
exact definition of these criteria what left to the discretion
of individual contractors. A detailed definition of these
terms was provided by the Medicare contractor for the
Northeast (MN, MS, NH, and VT) in October 2004.
Failure of conventional control was defined as failure to
control disease after prednisone 60 mg/d for 6 weeks
with or without a concurrent immunosuppressive agent
for 10-12 weeks. Contraindications to conventional
therapy with systemic steroids was defined the presence
of diabetes, significant osteoporosis, fractures, GI bleed-
ing, subscapular cataracts, pseudotumor cerebri, bone
marrow suppression, aplastic anemia, significant
psychological changes, steroid myopathy, or glaucoma.
Contraindications to conventional therapy with immuno-
suppressive agents was defined as persistent anemia;
clinically significant neutropenia, abnormal hepatic
function, or impaired renal function; hemorrhagic cystitis;
bone marrow suppression or history of malignancy. It
also added as an additional indication for IVIg treatment
the presence of significant adverse effects of conven-
tional therapy. These were defined as events which are
potentially life-threatening, cause significant morbidity or
inability to cope with activities of daily living, or require
the intervention of a physician or drug therapy. Of note,
is that patients may be taking these drugs to maintain
control of disease, and thus do not need to have active
disease at the time of initiation of the IVIg. Other
Medicare contractor or insurance companies may have
different definitions, and often limit the amount of Ig that
can be given and the frequency of the treatment. Con-
sequently, it is critical to contact and obtain authorization
from the patient’s own insurance carrier before initiating
IVIg treatment. 
Conclusions
IVIg is an important advance in the treatment of
pemphigus. It achieves the most sought after therapeu-
tic goal in the treatment of autoimmune diseases - the
selective removal of pathogenic antibodies without 
altering that of normal antibodies. 
IVIg seems particularly effective in the control of
active disease unresponsive to conventional therapy. It
is also useful as an adjunct to manage patients who have
developed serious complications to standard therapy, or
cannot be tapered off conventional therapy without a
flare in disease activity. The effectiveness of IVIg treat-
ment may be enhanced by repeating the procedure
frequently to speed the removal of pemphigus antibodies
and we believe by concurrently administering a cytotoxic
agent to prevent new synthesis of these antibodies. That
suggestion needs to be confirmed by appropriate clinical
trials.
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